GenomeFrontier provides a virus‑free gene‑editing platform called Quantum Engine™ that combines optimized electroporation (Quantum Nufect™), a high‑capacity transposon system (Quantum pBac™), scalable cell expansion (iCellar™), and gene design tools (G‑Tailor™) to produce therapeutic immune cells such as CAR‑T and TCR‑T therapies. The integrated workflow enables biopharma and academic developers to manufacture high‑viability, stable, and cost‑effective cell‑based gene therapies without viral vectors.
Funding
Funding not disclosed
Founders
Product
Problem
Current cell-modified gene therapies rely on viral vectors, which pose safety risks, have limited payload capacity, and are costly to manufacture. Additionally, delivering virus‑free vectors via electroporation damages cells, leading to low viability and poor expansion, hindering the production of sufficient, high‑quality therapeutic cells for clinical use.
Solution
GenomeFrontier addresses these challenges with its Quantum Engine™ platform, which combines four proprietary technologies: Quantum Nufect™ for efficient, low‑toxicity delivery of virus‑free vectors; Quantum pBac™ for stable, high‑capacity gene integration; iCellar™ for robust expansion of engineered cells while preserving stem‑like qualities; and G‑Tailor™ for optimized gene design. Together, these components enable the production of virus‑free, gene‑modified immune cells—such as CAR‑T and TCR‑T therapies—with high viability, scalable manufacturing, and sustained therapeutic gene expression, reducing safety concerns and manufacturing costs.
Target Audience
Primary customers are biopharmaceutical companies and academic research groups developing autologous cell‑based gene therapies, particularly those focused on CAR‑T and TCR‑T cancer treatments.
Features
- Quantum Nufect™ delivers virus‑free vectors using optimized electroporation that maintains cell viability and functional integrity.
- Quantum pBac™ provides a non‑viral transposon system capable of integrating large genetic payloads with stable, long‑term expression.
- iCellar™ combines artificial antigen‑presenting cells and Quantum Booster™ to expand CAR⁺ T cells up to 10⁹ cells in ten days while preserving a high proportion of stem‑cell memory (T SCM) phenotype.
- G‑Tailor™ designs therapeutic genes for optimal expression and minimal immunogenicity in the virus‑free context.
- Integrated workflow enables rapid, scalable manufacturing of clinical‑grade cell therapies without the need for viral production facilities.